Moderna Inc. (NASDAQ:MRNA) price on Wednesday, August 25, rose 0.74% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $397.87.
A look at the stock’s price movement, the close in the last trading session was $394.94, moving within a range at $387.97 and $413.80. The beta value (5-Year monthly) was 1.49 while the PE ratio in trailing twelve months stood at 49.67. Turning to its 52-week performance, $497.49 and $54.21 were the 52-week high and 52-week low respectively. Overall, MRNA moved 21.12% over the past month.
Moderna Inc.’s market cap currently stands at around $157.47 billion, with investors looking forward to this quarter’s earnings report slated for Oct 27, 2021 – Nov 01, 2021. Analysts project the company’s earnings per share (EPS) to be $5.95, which has seen fiscal year 2021 EPS growth forecast to increase to $29.54 and about $23.46 for fiscal year 2022. Per the data, EPS growth is expected to be 1,607.10% for 2021 and -20.60% for the next financial year.
Analysts have a consensus estimate of $4.21 billion for the company’s revenue for the quarter, with a low and high estimate of $2.87 billion and $5.47 billion respectively. The average forecast suggests up to a 6,241.20% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $20.28 billion, representing a 2,424.60% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
18 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 8 analyst(s) rate the stock as a Hold, 5 recommend MRNA as a Buy and 1 give it an Overweight rating. Meanwhile, 1 analyst(s) rate the stock as Underweight and 3 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 2.96, with MRNA’s current price about 1.00% and 29.26% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.43, while 7-day volatility ratio is 5.77% and 9.00% in the 30-day chart. Further, Moderna Inc. (MRNA) has a beta value of 0, and an average true range (ATR) of 32.88. Analysts have given the company’s stock an average 52-week price target of $290.83, forecast between a low of $85.00 and high of $463.00. Looking at the price targets, the low is 78.64% off current price level while to achieve the yearly target high, price needs to move -16.37%. Nonetheless, investors will most likely welcome a 31.76% jump to $271.50 which is the analysts’ median price.
In the market, a comparison of Moderna Inc. (MRNA) and its peers suggest the former has performed considerably stronger. Data shows MRNA’s intraday price has changed 0.74% in last session and 500.56% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.22% and 0.11% respectively in the last trading.
If we refocus on Moderna Inc. (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 16.89 million over the past 3 months. The company’s latest data on shares outstanding shows there are 402.00 million shares.
The 2.50% of Moderna Inc.’s shares are in the hands of company insiders while institutional holders own 57.90% of the company’s shares. Current price change has pushed the stock 280.85% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.